SCHEMBL12877014

SCHEMBL12877014

Cc1cccc(-c2cnc(Cc3ccc(C(=O)O)cc3)s2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.56
HSD17B1 P14061 2/20 0.47
HSD17B2 P37059 2/20 0.47
ERCC5 P28715 1/20 0.46
FEN1 P39748 1/20 0.46
CSNK2A1 P68400 1/20 0.45
LOXL2 Q9Y4K0 2/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
KDM4E B2RXH2 2/20 0.42
NPC1 O15118 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
SRD5A2 P31213 1/20 0.42
MAP3K8 P41279 1/20 0.41
IP6K1 Q92551 1/20 0.40
IP6K3 Q96PC2 1/20 0.40
IP6K2 Q9UHH9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12877012 0.87 SYK (0.47) SYKHSD17B1HSD17B2ERCC5FEN1
SCHEMBL1199228 0.84 ALDH1A1 (0.52) SYKERCC5FEN1CSNK2A1HDAC6
SCHEMBL12876983 0.80 HDAC6 (0.59) CSNK2A1HDAC6KDM4ENPC1MAPT
SCHEMBL12876806 0.79 RARA (0.53) SYKKDM4ENPC1POLBMAPT
SCHEMBL12875720 0.77 HSD17B1 (0.47) SYKHSD17B1HSD17B2ERCC5FEN1
SCHEMBL12688213 0.76 HSD17B1 (0.65) HSD17B1HSD17B2ERCC5FEN1HDAC1
SCHEMBL12875717 0.76 HSD17B1 (0.51) HSD17B1HSD17B2ERCC5FEN1LOXL2
SCHEMBL12876767 0.76 SIRT5 (0.50) CSNK2A1HDAC6KDM4ENPC1POLB
SCHEMBL12495956 0.75 HSD17B1 (0.64) HSD17B1HSD17B2ERCC5FEN1HDAC1
SCHEMBL12876907 0.75 RARB (0.54) KDM4ENPC1MAPTRAB9ASRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A SYK 360/4885HSD17B1 248/4885HSD17B2 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.